At Coherus, we put patients first.

We are dedicated to improving the availability of high-value, high-quality therapeutics. Our pipeline and product portfolio spans multiple therapeutic areas including oncology, immunology, and ophthalmology.

We market UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta® in the U.S., and CIMERLI™ (ranibizumab-eqrn) biosimilar of Lucentis® in the U.S. our Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) is approved in the U.S. and is expected to be available for patients in 2023.

Our strategy is to invest cash flows from our commercial biosimilar business to build animmuno-oncology franchise that will be synergistic with our proven commercial capabilities in oncology.

In 2021, we in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of nasopharyngeal carcinoma is under review by the FDA with a target action date of December 23, 2022.

Our earlier-stage immuno-oncology pipeline includes CHS-006, a TIGIT-targeted antibody, being evaluated in combination with toripalimab, and other immuno-therapies targeting novel pathways such as ILT4, CCR8 and CD73.